Tests fexofenadine added to standard care after heart attack treatment
Tests fexofenadine against placebo in adults with ST-elevation heart attack after stenting.
Plain-language title generated from the registry record
Registry title: Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a heart attack of the STEMI type, had emergency artery treatment, and still have reduced heart pumping.
- Age
- Above 18 years
- Sex
- All sexes can join
- Disease stage
- STEMI (heart attack with ST segment elevation) confirmed by chest pain over 30 minutes, raised cTn, and new ST segment elevation on the ECG. Emergency coronary angiography and revascularization must be done. Within 72 hours after revascularization, heart ultrasound shows a wall motion abnormality and LVEF ≤ 50%.
- Earlier treatment
- Must have had emergency coronary angiography and revascularization. Cannot have used fexofenadine hydrochloride or other H1 receptor inhibitors long term, or have had a heart attack or coronary artery bypass grafting before.
- Biomarker or test result
- Serum cTn at least once higher than the upper limit of normal (99th percentile of the reference upper limit). LVEF ≤ 50% on heart ultrasound within 72 hours after revascularization.
Main reasons for not taking part
- Earlier myocardial infarction or coronary artery bypass grafting
- Cardiomyopathy or valve disease
- Severe renal failure (eGFR < 30ml/min) or severe liver dysfunction
- Pregnant or potentially pregnant women, and breastfeeding women
- Hemodynamic instability
Read by machine on 12 November 2026.
Where in China
- The 2nd Affiliated Hopital of Zhejiang University, School of MedicineHangzhou, ChinaContact: Prof. Yinchuan XuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06548204
- Record updated
- 16 September 2026
- Original description
The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.Read full original descriptionShow less
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
Inclusion: Ages above 18; Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial; Meet the diagnostic criteria for STEMI, the diagnostic criteria includes:; Clinical symptoms: ischemic chest pain lasting for over 30 minites; Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit); ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG; Emergency coronary angiography and revascularization should be performed; Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization.
Exclusion: Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors; Previously suffered from myocardial infarction or received coronary artery bypass grafting; Patients with concomitant cardiomyopathy or valve disease; Currently receiving immunosuppressive therapy; History of severe liver dysfunction; Concurrent severe infections, or liver/gallbladder obstruction, or history of malignant tumors; Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations; History of severe renal failure, estimated glomerular filtration rate (eGFR) < 30ml/min; Pregnant or potentially pregnant and breastfeeding women; Without obtaining written informed consent; Patients with hemodynamic instability.